A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003142
- Lead Sponsor
- Guangdong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Meet the diagnostic criteria for patients with COVID-19 of the Proposal of Diagnosis and Treatment of COVID-19;
(2) Aged 18-85 years;
(3) To agree to participate in the study and sign the informed consent
(1) Critical patients;
(2) TCM diagnosis of yang deficiency syndrome, manifested as limb warm, thin stools, chills, etc.;
(3) Patients who cannot guarantee compliance during treatment, and patients who are difficult to administer by oral or nasal route;
(4) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19;
(5) Pregnant and mothers, those who have a pregnancy plan, and those who have a positive urine pregnancy test;
(6) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study;
(7) People who have been allergic to Chinese medicine or intolerant to taking medicine.
(8) Patients are participating in other COVID-19 clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inflammation absorption on Chest CT;
- Secondary Outcome Measures
Name Time Method Total hospitalized time;side effects associated with interventions;